Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab [Yahoo! Finance]
Jasper Therapeutics, Inc. - Class A (JSPR)
Company Research
Source: Yahoo! Finance
UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term durability data, with limited near-term catalysts, before topline data from the BEACON Phase 2b study in chronic spontaneous urticaria, or CSU, expected in 2027. Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab The call came after Jasper had already reported updated data for briquilimab on January 8. The company said 67% of additional patients treated with briquilimab in the BEACON Phase 1b/2a study achieved a complete response at 12 weeks, while 83% achieved a complete response by week 3 after the initial dose. Jasper also said the BEACON and open-label extension data were enough to support dose selection for a Phase 2b study in CSU planned to begin in the second half of 2026. Jasper Therapeutics, Inc. (NASDAQ:JSP
Show less
Read more
Impact Snapshot
Event Time:
JSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JSPR alerts
High impacting Jasper Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
JSPR
News
- Jasper Therapeutics GAAP EPS of -$0.32 beats by $0.48 [Seeking Alpha]Seeking Alpha
- Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- Jasper Therapeutics (JSPR) is now covered by UBS Group AG. They set a "neutral" rating and a $1.50 price target on the stock.MarketBeat
- Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare ConferenceGlobeNewswire
JSPR
Earnings
- 3/30/26 - Beat
JSPR
Sec Filings
- 3/30/26 - Form 8-K
- 3/30/26 - Form 10-K
- 2/25/26 - Form SCHEDULE
- JSPR's page on the SEC website